From: Boris Nikolic

From: Boris Nikolic To: Gene Walther , CC: ehud barak Subject: FW: Parasight Ltd. Date: Mon, 12 Aug 2013 04:40:53 +0000 Attachments: PARASIGHT_EXECUTIVE_SUMMARY_V1.8.pdfi ATT00001.htm; CL- IN002_Report_signed.pdf; ATT00002.htm Thank you Ehud! We will follow up for sure. I am sending this to Gene Walther who is leading diagnostics (including malaria diagnostics) at Bill and Melinda Gates Foundation. I think that Gene is on business travel and vacation right now so it might be some delay. Looking forward to learning more re this promising technology! All the best Boris From: thud barak [milt° Sent: Sunday, August 11, 2013 9:51 AM To: Boris Nikolic Subject: Fwd: Parasight Ltd. Dear Boris Attached as promised p1 find Parasight presentation. PI send me your initial response and we'll consider how to continue \A ith them. Best Ehud Barak Sent from my iPhone Begin forwarded message: From: Doron Date: August 11, 2013 18:52:33 GMT+03:00 To: Ehud BARAK Subject: Fwd: Parasight Ltd. EFTA00967515 Dear Dr. Nikolic, Parasight Ltd was founded two years ago in Israel in order to develop a platform technology for blood analysis and parasite detection. During this time, Parasight has focused on developing an innovative device for the accurate, rapid and inexpensive diagnosis of Malaria, suitable for POC and labs in Malaria-endemic countries as well as blood banks everywhere. The device is based on the latest technologies in the field of machine-vision together with breakthrough advances in sample preparation and staining. Following Mr. Barak's communication with you, we are proud to present the official report describing the results of our first clinical trial, which was conducted recently in India by the National Institute of Malaria Research. As the report indicates, our clinical accuracy is on par with PCR, but with ease of use and cost commensurate with RDTs. Additionally, I am attaching an executive summary describing the company. Our goal is to introduce Parasight's technology to the Gates Foundation in hopes of advancing the project and reaching the target population. As it happens, our co-founder and Chairman of the Scientific Advisory Board, Dr. Daniel Levner, is a Senior Staff Scientist at Harvard Medical School, so perhaps the best way to present our technology would be through a meeting. Please let me know what would be best for you. Thanks, Vossi Pollak Chief Executive Officer EFTA00967516